RxDoctor Payments Data

Edwin Rozario, MD

Family Medicine · Wheeling, WVNPI 1780004093

Payments from drug & device makers

$839in general payments, 2019–2025

Across 13 payments — averaging $64.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mannkind Corporation$212
  • Novo Nordisk$125
  • Sanofi-aventis U.S. LLC$92
  • Corcept Therapeutics$91
  • Boehringer Ingelheim$88
  • Bayer$75
  • plus $156 from 4 others

What the payments were for

  • Food & beverage$839100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$839 in reported general payments places this provider in the 65th percentile of 843 family medicine providers in West Virginia.

See all family medicine providers in West Virginia

Medicare billing

Part B allowed, 2024
$74,349
Medicare patients
236
Services billed
849

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban114$103,507
OzempicSemaglutide66$74,842
XareltoRivaroxaban56$63,365
JanuviaSitagliptin Phosphate67$54,622
MounjaroTirzepatide28$41,755
JardianceEmpagliflozin32$38,759
JanumetSitagliptin Phos/Metformin Hcl16$13,404
LinzessLinaclotide16$12,326
Repatha SureclickEvolocumab15$11,739
Lantus SolostarInsulin Glargine,hum.Rec.Anlog66$10,924
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$9,602
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$7,901
SymbicortBudesonide/Formoterol Fumarate14$6,600
Atorvastatin Calcium613$5,871
Omeprazole418$5,756

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$125$74,84266 claims
Boehringer IngelheimJardiance$88$38,75932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 843 family medicine providers in West Virginia.

Other family medicine in Wheeling

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →